NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) prevalence in women is increasing worldwide. Women of reproductive age have lower rates of NAFLD compared with men; however, this protection is lost following the menopausal transition when NAFLD prevalence in postmenopausal women becomes similar to or surpasses that in age-matched male counterparts. Ongoing epidemiological, clinical, and experimental studies indicate greater NAFLD risk and higher rates of severe hepatic fibrosis in postmenopausal women relative to premenopausal women, and that older women with NAFLD experience greater mortality than men. Investigations involving ovariectomized animal models demonstrate a causal relationship between estrogen deficiency and heightened susceptibility to the development of fatty liver and steatohepatitis, although dietary factors may exacerbate this complex relationship. The accumulated findings suggest that a better understanding of the interplay among menopausal status, metabolic comorbidities, and sex steroids in NAFLD pathogenesis is needed. Further, the mechanisms underlying the difference in NAFLD risk between postmenopausal and premenopausal women remain incompletely understood. The goals of this review are to summarize studies of NAFLD risk in postmenopausal women, discuss results from animal models of estrogen deficiency, and explore the development of NAFD within the context of altered sex hormone profiles resulting from the menopausal transition. Potential implications for the prevention, diagnosis, and treatment of NAFLD in this relatively understudied cohort are also addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Increased visceral fat and decreased energy expenditure during the menopausal transition
Lovejoy, J. C., Champagne, C. M., de Jonge, L., Xie, H., & Smith, S. R. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.25 · Cited by 1,020
White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766
Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice
Riant, E., Waget, A., Cogo, H., Arnal, J.-F., Burcelin, R., & Gourdy, P. (2009) · Endocrinology · doi:10.1210/en.2008-0971 · Cited by 421
Why Visceral Fat is Bad: Mechanisms of the Metabolic Syndrome
Bergman, R. N., Kim, S. P., Catalano, K. J., Hsu, I. R., Chiu, J. D., Kabir, M., Hucking, K., & Ader, M. (2006) · Obesity · doi:10.1038/oby.2006.277 · Cited by 371
Zhu, L., Brown, W. C., Cai, Q., Krust, A., Chambon, P., McGuinness, O. P., & Stafford, J. M. (2013) · Diabetes · doi:10.2337/db11-1718 · Cited by 326
Camporez, J. P., Lyu, K., Goldberg, E. L., Zhang, D., Cline, G. W., Jurczak, M. J., Dixit, V. D., Petersen, K. F., & Shulman, G. I. (2019) · The Journal of Physiology · doi:10.1113/jp277270 · Cited by 71
Yoneda, M., Thomas, E., Sumida, Y., Eguchi, Y., & Schiff, E. R. (2014) · Hepatology · doi:10.1002/hep.27097 · Cited by 45
Cited by
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“Nonalcoholic fatty liver disease is more common after the menopause transition when the prevalence surpasses men.(191)”
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
Tamaki, N., Ahlholm, N., Luukkonen, P. K., Porthan, K., Sharpton, S. R., Ajmera, V., Kono, Y., Dave, S., Ahmed, A., Sundaram, V., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162513 · Cited by 69
Park, W. Y., Yiannakou, I., Petersen, J. M., Hoffmann, U., Ma, J., & Long, M. T. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.11.001 · Cited by 53
Jaroenlapnopparat, A., Charoenngam, N., Ponvilawan, B., Mariano, M., Thongpiya, J., & Yingchoncharoen, P. (2023) · Menopause · doi:10.1097/gme.0000000000002133 · Cited by 48
Metadata
- Authors
- DiStefano, J. K.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2020-08-11
- Volume
- 161
- Issue
- 10
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W3048422378
- Cited by
- 228
- References
- 14
- FWCI
- 14.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.